Florian Lordick

List of Publications by Year
in descending order

118 papers	16,158 citations	87401 40 h-index	37326 100 g-index
126 all docs	126 docs citations	126 times ranked	15332 citing authors

#	Article	IF	Citations
1	Targeting HER2 for localised oesophageal cancer. Lancet Oncology, The, 2022, 23, 188-190.	5.1	0
2	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer, 2022, 164, 18-29.	1.3	27
3	Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapiesâ€"the role of HAS2, SHB and HBEGF. BMC Cancer, 2022, 22, 254.	1.1	4
4	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€3). International Journal of Cancer, 2022, 150, 1341-1349.	2.3	6
5	Adjuvant radiotherapy for gastric cancerâ€"end of the road?. Annals of Oncology, 2021, 32, 287-289.	0.6	16
6	PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. OncoImmunology, 2021, 10, 1960729.	2.1	8
7	Targeted and immunotherapy in the era of personalised gastric cancer treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 50-51, 101738.	1.0	15
8	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nature Reviews Clinical Oncology, 2021, 18, 473-487.	12.5	139
9	Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. Oncologist, 2021, 26, e1058-e1065.	1.9	42
10	Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+â€‰gastroesophageal adenocarcinoma. Gastric Cancer, 2021, 24, 721-730.	2.7	23
11	Psychosocial aftercare of adolescent and young adult cancer survivors in Germany: Awareness, utilisation, satisfaction and associated factors. Psycho-Oncology, 2021, 30, 1311-1321.	1.0	4
12	HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. Journal of Clinical Oncology, 2021, 39, 1468-1478.	0.8	54
13	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. Cancers, 2021, 13, 5216.	1.7	15
14	Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data. Obesity, 2021, 29, 294-301.	1.5	3
15	SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 82.	1.8	3
16	Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. Cancers, 2021, 13, 5975.	1.7	6
17	Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncology Research and Treatment, 2020, 43, 42-47.	0.8	8
18	Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 135-144.	2.9	39

#	Article	IF	Citations
19	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. European Journal of Cancer, 2020, 124, 67-76.	1.3	16
20	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 2020, 5, e001090.	2.0	18
21	Ãœberleben mit QualitÃt. Forum, 2020, 35, 355-355.	0.0	0
22	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open, 2020, 5, e000826.	2.0	60
23	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. ESMO Open, 2020, 5, e000804.	2.0	61
24	Gastric cancer. Lancet, The, 2020, 396, 635-648.	6.3	2,084
25	Technik fÃ¼r das Leben. Forum, 2020, 35, 257-257.	0.0	0
26	Reif fÃ¼r die Insel. Forum, 2020, 35, 433-433.	0.0	0
27	Young patients with cancer and a digital social network: the voice beyond the clinic. ESMO Open, 2020, 5, e000651.	2.0	9
28	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	1.1	0
29	Die digitale Revolution erreicht die Onkologie. Forum, 2020, 35, 81-81.	0.0	0
30	Progress and challenges in gastroesophageal cancer. Current Problems in Cancer, 2020, 44, 100590.	1.0	5
31	Ein bewegtes 2019. Forum, 2019, 34, 1-1.	0.0	0
32	Leitlinien und Innovation â€“ keinÂWiderspruch. Forum, 2019, 34, 223-224.	0.0	0
33	A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology, 2019, 30, 1487-1495.	0.6	130
34	Zu viel Recht?. Forum, 2019, 34, 399-399.	0.0	0
35	Zu viel ist nicht gut. Forum, 2019, 34, 305-305.	0.0	0
36	Social networks for young patients with cancer: the time for system agility. Lancet Oncology, The, 2019, 20, 765.	5.1	11

#	Article	IF	Citations
37	High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFRâ€“directed monoclonal antibody (EXPAND trial) showing no prognostic impact. European Journal of Cancer, 2019, 116, 107-113.	1.3	2
38	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. European Journal of Cancer, 2019, 112, 1-8.	1.3	23
39	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. Cancers, 2019, 11, 187.	1.7	20
40	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. ESMO Open, 2019, 4, e000533.	2.0	1
41	Zwei Dekaden gegen den Krebs. Forum, 2019, 34, 489-489.	0.0	0
42	Two steps forward and one step back. Nature Reviews Clinical Oncology, 2019, 16, 69-70.	12.5	6
43	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or) Tj ETQq1 1 0.784314 rgBT /Over	7.8	87
44	Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer. Oncotarget, 2019, 10, 4731-4742.	0.8	15
45	Anti-angiogenics in Gastroesophageal Cancer. , 2019, , 395-414.		0
46	Perioperative chemotherapy with or without epidermal growth factor receptorÂblockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer, 2018, 93, 119-126.	1.3	33
47	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Critical Reviews in Oncology/Hematology, 2018, 122, 179-193.	2.0	57
48	Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. European Journal of Surgical Oncology, 2018, 44, 626-631.	0.5	16
49	Changing paradigms in adjuvant treatment of colorectal cancer. The Lancet Gastroenterology and Hepatology, 2018, 3, 6-8.	3.7	4
50	PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 51-60.	1.1	14
51	Krebs ist teuer â€“ eine Frage derÂPerspektive. Forum, 2018, 33, 299-301.	0.0	0
52	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. Journal of Gastric Cancer, 2018, 18, 379.	0.9	54
53	Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. British Journal of Cancer, 2018, 119, 170-175.	2.9	6
54	Randomised phase II trial to investigate catumaxomab (anti-EpCAMâ€‰Ã—â€‰anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. British Journal of Cancer, 2018, 119, 296-302.	2.9	60

#	Article	IF	Citations
55	More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. European Journal of Cancer, 2018, 97, 25-26.	1.3	0
56	Ã–sophaguskarzinom beim alten und geriatrischen Patienten. , 2018, , 313-324.		0
57	Anti-angiogenesis: disappointment in localised oesophagogastric cancer. Lancet Oncology, The, 2017, 18, 278-279.	5.1	4
58	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer, 2017, 20, 904-912.	2.7	33
59	Salvage chemotherapy for advanced gastric cancer: more than a false hope?. The Lancet Gastroenterology and Hepatology, 2017, 2, 240-241.	3.7	0
60	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 2017, 24, 2252-2258.	0.7	186
61	Anti-Angiogenics in Gastroesophageal Cancer. , 2017, , 1-19.		0
62	HER2 testing in gastric cancer: results of a German expert meeting. Journal of Cancer Research and Clinical Oncology, 2017, 143, 835-841.	1.2	46
63	Management of Metastatic Gastric Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 469-483.	0.9	16
64	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. JAMA Oncology, 2017, 3, 620.	3.4	233
65	Treatment of oesophageal cancer â€“ Stressing the patient perspective. European Journal of Cancer, 2017, 84, 360-362.	1.3	1
66	Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer?. European Journal of Surgical Oncology, 2017, 43, 1835-1845.	0.5	4
67	Oesophageal cancer. Nature Reviews Disease Primers, 2017, 3, 17048.	18.1	671
68	Oligometastases of Gastrointestinal Cancer Origin. Visceral Medicine, 2017, 33, 76-81.	0.5	0
69	Ã–sophaguskarzinom beim alten und geriatrischen Patienten. , 2017, , 1-12.		0
70	Gastric cancer adjuvant therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 581-591.	1.0	13
71	Insights into next developments in advanced gastric cancer. Current Opinion in Oncology, 2016, 28, 367-375.	1.1	16
72	Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innovative Surgical Sciences, 2016, 1, 3-11.	0.4	6

#	Article	IF	Citations
73	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 2016, 16, 503.	1.1	234
74	Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Medicine, 2016, 5, 1444-1453.	1.3	50
75	Death-Related Anxiety in Patients With Advanced Cancer: Validation of the German Version of the Death and Dying Distress Scale. Journal of Pain and Symptom Management, 2016, 52, 582-587.	0.6	34
76	Symptoms and Needs of Head and Neck Cancer Patients at Diagnosis of Incurability - Prevalences, Clinical Implications, and Feasibility of a Prospective Longitudinal Multicenter Cohort Study. Oncology Research and Treatment, 2016, 39, 186-191.	0.8	20
77	Der Patient im Mittelpunkt. Forum, 2016, 31, 89-90.	0.0	0
78	Clinical impact of tumour biology in the management of gastroesophageal cancer. Nature Reviews Clinical Oncology, 2016, 13, 348-360.	12.5	132
79	Perioperative and Palliative Chemotherapy for Esophageal Cancer. Visceral Medicine, 2015, 31, 341-346.	0.5	2
80	Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. European Journal of Cancer, 2015, 51, 569-576.	1.3	59
81	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international,) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	84
82	Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial. BMC Cancer, 2015, 15, 592.	1.1	42
83	Over the RAINBOWâ€"renaissance in antiangiogenesis. Nature Reviews Clinical Oncology, 2015, 12, 7-8.	12.5	8
84	Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU. Strahlentherapie Und Onkologie, 2014, 190, 1133-1140.	1.0	16
85	Unmet needs and challenges in gastric cancer: The way forward. Cancer Treatment Reviews, 2014, 40, 692-700.	3.4	156
86	Targeting the HGF/MET pathway in gastric cancer. Lancet Oncology, The, 2014, 15, 914-916.	5.1	28
87	Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer, 2014, 17, 213-225.	2.7	103
88	Rectal Cancer with Synchronous Liver Metastases: Leave It All in? When (not) to Resect the Primary?. Recent Results in Cancer Research, 2014, 203, 231-241.	1.8	1
89	Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget, 2014, 5, 6620-6632.	0.8	35
90	Proteomic and metabolic prediction of response to therapy in gastric cancer. World Journal of Gastroenterology, 2014, 20, 13648.	1.4	20

#	Article	IF	Citations
91	Multimodal treatment of esophageal cancer. Langenbeck's Archives of Surgery, 2013, 398, 177-187.	0.8	46
92	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 490-499.	5.1	740
93	Salvage chemotherapy in gastric cancerâ€"more than a straw?. Nature Reviews Clinical Oncology, 2012, 9, 312-313.	12.5	8
94	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer â€“ Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer, 2012, 48, 2941-2953.	1.3	129
95	Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer, 2012, 12, 142.	1.1	115
96	Optimizing Neoadjuvant Chemotherapy Through the Use of Early Response Evaluation by Positron Emission Tomography. Recent Results in Cancer Research, 2012, 196, 201-211.	1.8	18
97	How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. Current Opinion in Oncology, 2011, 23, 396-402.	1.1	26
98	HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. Clinical and Translational Oncology, 2011, 13, 597-598.	1.2	6
99	Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 2011, 11, 509.	1.1	58
100	Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. Journal of Clinical Oncology, 2010, 28, 5210-5218.	0.8	619
101	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, The, 2010, 376, 687-697.	6.3	5,899
102	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncology, The, 2010, 11, 38-47.	5.1	873
103	Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Modern Pathology, 2009, 22, 1555-1563.	2.9	101
104	Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center. Annals of Surgical Oncology, 2009, 16, 1017-1025.	0.7	79
105	The role of biologics in stomach cancer. Targeted Oncology, 2008, 3, 71-79.	1.7	3
106	The evolving role of catumaxomab in gastric cancer. Expert Opinion on Biological Therapy, 2008, 8, 1407-1415.	1.4	14
107	Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, 187-97.	0.8	7
108	PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncology, The, 2007, 8, 797-805.	5.1	757

#	Article	IF	Citations
109	Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis. Journal of Nuclear Medicine, 2007, 48, 1945-1950.	2.8	113
110	Current treatment approach to locally advanced esophageal cancer: is resection mandatory?. Future Oncology, 2006, 2, 717-721.	1.1	15
111	Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1295-1298.	0.4	128
112	The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer, 2006, 106, 2119-2127.	2.0	131
113	Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction. Journal of Clinical Oncology, 2006, 24, 4692-4698.	0.8	458
114	Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer, 2005, 8, 78-85.	2.7	80
115	Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. Journal of Nuclear Medicine, 2005, 46, 2029-34.	2.8	71
116	Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. British Journal of Haematology, 2003, 120, 1073-1078.	1.2	65
117	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		1
118	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		3